Asked by: Baroness Jones of Moulsecoomb (Green Party - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to ensure that the proposed WHO Pandemic Preparedness Treaty, due to be considered by the 77th World Health Assembly in May, will include provisions to improve indoor air quality.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom welcomes the Pandemic Accord as an opportunity to strengthen global health security. Improving indoor air quality remains an important issue in public health. However, as the Accord aims to establish a high-level framework for pandemic prevention, preparedness and response, we have pursued action on this specific issue in other multilateral settings.
The UK continues to support international improvements to indoor air pollution through its engagement with the World Health Organization (WHO). For example, the UK Health Security Agency (UKHSA) contributed to WHO projects in 2020 and 2022 to assess combined exposure to multiple chemicals in indoor air in schools. UKHSA continues to work with the International Society on Indoor Air Quality and Climate on the development of an open database on international indoor environmental quality guidelines. The database aims to be actively used by researchers, practitioners, and policymakers across the world.
Moreover, the UK was a strong advocate for action to improve indoor air quality at last year’s United Nations General Assembly. We worked with international partners on this issue during the High-Level Meeting on Universal Health Coverage. The UK was supportive of reference being made to the health impacts of indoor air pollution, which was subsequently adopted in the meeting’s political declaration on 5 October 2023, and is available on the United Nations website in an online-only format.
Asked by: Baroness Jenkin of Kennington (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, following the Food Data Transparency Partnership’s decision not to make reporting on health data mandatory, what steps they are taking to ensure enforcement of and consistency in the voluntary scheme.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Food Data Transparency Partnership’s (FDTP) Health Working Group (HWG) has been testing the effectiveness and quality of potential standardised metrics that food and drink companies can use to report on the healthiness of their sales. This is an important part of government’s strategy to address poor diet and reduce obesity and was restated in the Major Conditions Strategy interim report August 2023.
Once a recommended set of metrics and reporting guidance has been produced and approved by Ministers, the expectation is that businesses who voluntarily report will all follow this standardised approach.
A key commitment of the HWG is timely and transparent communication so that wider food sector stakeholders can input into each stage of the process in order to ensure recommendations around comparability and enforcement will be as viable and effective as possible. Alongside engagement with industry, the FDTP also regularly engages civil society organisations and investor groups to gather and integrate wider feedback into discussions. Summaries of these HWG discussions are published online on the FDTP GOV.UK page.
Asked by: Lord Swire (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what progress they have made on integrating social care and the NHS.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Health and Care Act 2022 established integrated care systems, reforming how health and adult social care work together by putting partnership at the heart of planning. The Government has published guidance for integrated care partnerships (ICPs), on the statutory requirement for each ICP to publish an Integrated Care Strategy to address the health, social care, and public health needs of their system. All ICPs have now published their integrated care strategies.
The integration of health and social care is often best achieved through collaboration across smaller geographies within integrated care systems called places. Since the Health and Care Act 2022, we have seen good progress in the development of place-based arrangements to integrate health and social care. In October 2023, we published our Shared Outcomes Toolkit designed to help place-based partnerships develop shared outcomes as a powerful means of promoting integrated working and joined up care. We also issued a call for evidence as part of our review of Section 75 of the NHS Act 2006, which permits local authorities and National Health Service bodies to pool budgets, enabling joint commissioning and the commissioning of integrated services. The findings of this review will be shared in due course.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the number of people participating in smoking cessation programmes.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Smoking is the number one entirely preventable cause of ill-health, disability and death in this country. It is responsible for 80,000 yearly deaths in the United Kingdom and one in four of all UK cancer deaths. It costs our country £17 billion a year, £14 billion of which is through lost productivity alone. It puts a huge pressure on the National Health Service and social care, costing over £3 billion a year. Quitting smoking is the best thing a smoker can do for their health and smokers are three times as likely to succeed with stop smoking services (SSS) when compared to an unsupported quit attempt.
As announced in Stopping the start: our new plan to create a smokefree generation, published in October 2023, the Government is investing an additional £70 million per year for five years to support local authority-led SSS, around doubling current spend and supporting 360,000 people to set a quit date each year. To support engagement with SSS, and increase motivation to quit, we are spending an additional £15 million per year to fund national anti-smoking campaigns. We are also investing up to £45 million over two years to roll out our national ‘Swap to Stop’ scheme and establishing a financial incentives scheme to help pregnant smokers and their partners quit smoking with smoking cessation support.
Vaping is never recommended for children, and carries the potential harms of future addiction while their lungs and brains are still developing. The health advice is clear, vapes can be an effective tool to help smokers quit, but young people and those who have never smoked should not vape, or be encouraged to vape.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of vaping on the health of pregnant women; and whether she plans to take steps to encourage pregnant women to stop vaping.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Our health advice on vaping is clear, if you smoke, it is better to vape, but if you don’t smoke, you should never vape. Evidence to date suggests vaping is less harmful than smoking. Research funded by the National Institute for Health and Care Research finds that pregnant women who vaped, when compared to women who used Nicotine Replacement Therapy, were twice as likely to quit, and that both approaches were safer than smoking. Further information is available at the following link:
https://www.nature.com/articles/s41591-022-01808-0
To help pregnant smokers quit smoking, the Government is providing up to £10 million of investment over 2023/24 and 2024/25 via a financial incentives scheme. This evidence-based intervention, supported by behavioural support, will encourage pregnant women to quit smoking, and remain smokefree throughout pregnancy and beyond, helping to improve the health and wellbeing of both mother and baby.
Asked by: Navendu Mishra (Labour - Stockport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to provide mental health support for the dental workforce.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS Long Term Workforce Plan commits the National Health Service to supporting staff health and wellbeing, and asks integrated care systems to develop plans to support NHS staff in maintaining their mental health.
The NHS dental workforce is also able to access the NHS Practitioner Health Service. NHS England is in the process of reviewing the service as part of a wider review into its mental health and wellbeing offer to all staff, including the dental workforce.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the potential merits of creating a national naloxone programme.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the availability of naloxone across England.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is taking steps to increase awareness of naloxone.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Ellie Reeves (Labour - Lewisham West and Penge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that NHS integrated care boards commission (a) end-of-life and (b) other palliative care for people in all age groups.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
While the National Health Service has always been required to commission appropriate palliative and end of life care services to meet the reasonable needs of their population, in 2022, palliative care services were added to the list of services an integrated care board (ICB) must commission, promoting a more consistent national approach and supporting commissioners in prioritising palliative and end of life care in all settings. To support ICBs in this duty, NHS England has published statutory guidance and service specifications for both adults and children.
From April 2024, NHS England will include palliative and end of life care in the list of topics for its regular performance discussions between national and regional leads. Additionally, NHS England has commissioned the development of a palliative and end of life care dashboard, which brings together relevant, all age local data in one place. The dashboard helps commissioners understand the palliative and end of life care needs of both adults and children in their local population, enabling ICBs to put plans in place to address and track the improvement of health inequalities.
NHS England has also funded seven Palliative and End of Life Care Strategic Clinical Networks, each with a dedicated Children and Young People Lead. These networks support commissioners in the delivery of outstanding clinical and personalised care for people in the last year of life and reduce local variation.